Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Davies, Andy
ACCEPT, NCT03571308 / 2015-003213-18: A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)	Completed	1/2	39	Europe	R-CHOP + acalabrutinib, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisolone, Acalabrutinib	University Hospital Southampton NHS Foundation Trust	Non Hodgkin Lymphoma	01/20	08/23
CCS1477-02, NCT04068597 / 2019-000104-15: Study to Evaluate CCS1477 in Haematological Malignancies	Recruiting	1/2	250	Europe, US	CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax	CellCentric Ltd.	Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma	06/25	06/25